The hepatitis C field is living a revolution following the introduction of all-oral therapies that can cure most patients with short courses of direct-acting antiviral (DAA) combinations. Given that chronic hepatitis C affects globally around 20% of HIV persons, major attention has been focused on the HIV/HCV-coinfected population. Current evidence suggests that these patients depict cure rates of over 90%, similar to HCV-monoinfected individuals. Accordingly, current guidelines for hepatitis C therapy no longer separate mono- and coinfected subjects.